BioMarin Analysis
What is BioMarin?
Biotechnology company focused on rare genetic diseases
Employees
1001-5000
Founded
1997
Valuation
$13.03 billion
Revenue Growth Rate
15.42%
Product Features & Capabilities
- PALYNZIQ® for phenylketonuria
- Vimizim® for Morquio A syndrome
- Naglazyme® for MPS VI
- Kovanaze® for dental anesthesia
- Brineura® for CLN2 disease
- Kuvan® for phenylketonuria
- Roctavian® for hemophilia A
- Valoctocogene roxaparvovec for hemophilia A
Use Cases
Treat severe hemophilia A with Roctavian®; Manage phenylketonuria using PALYNZIQ®; Provide enzyme replacement therapy for MPS VI with Naglazyme®; Support dental procedures with Kovanaze®; Address Morquio A syndrome with Vimizim®
Investment Focus
- Central Nervous System - Targeting conditions affecting the brain and spinal cord.
- Cardiovascular - Addressing heart-related diseases.
- Musculoskeletal/Metabolic - Focusing on disorders related to muscles, bones, and metabolic processes.
- Non-Oncology - Developing therapies for various non-cancerous conditions.
Additionally, BioMarin specializes in treatments for rare genetic diseases, including enzyme replacement therapies for conditions like achondroplasia and severe hemophilia A.
Other Considerations
Serves patients with eight marketed products; Recognized for leadership in rare disease treatment; Active in clinical trials for investigational therapies; Engages with patient communities for better care solutions
Awards Recognition
- 2023 Pantheon Awards - BioMarin was recognized for its innovative achievements in biotechnology alongside Twist Bioscience.
- Company of the Year - BioMarin was honored as Company of the Year in the Biopharma category at the California Life Sciences (CLS) awards in November 2023.
- WORLDSymposium 2018 New Treatment Award - Their therapy Brineura (cerliponase alfa) received this award for its achievements in treating Batten disease.
- Forbes Ranking - BioMarin was ranked 12th on Forbes magazine's list of the "World's Most Innovative Companies" in 2017.
- ISPE Facility of the Year Award - Their gene therapy manufacturing facility was recognized for innovation and creativity in the pharmaceutical and biotechnology sectors.
Key Innovations
BioMarin Pharmaceutical has developed several key innovations and products in the biotech sector, particularly focused on rare diseases. Notable products include:
- Aldurazyme® (laronidase) - A treatment for Mucopolysaccharidosis I (MPS I).
- Brineura® (cerliponase alfa) - Used for treating CLN2 disease, a form of Batten disease.
- Kuvan® (sapropterin dihydrochloride) - A treatment for phenylketonuria (PKU).
- Naglazyme® (galsulfase) - For MPS VI treatment.
- Palynziq® (pegvaliase-pqpz) - Another treatment for PKU.
- Roctavian™ (valoctocogene roxaparvovec-rvox) - A gene therapy for hemophilia A.
- Vimizim® (elosulfase alfa) - For MPS IVA treatment.
- Voxzogo® (vosoritide) - A treatment for achondroplasia.
These products represent significant innovations in the treatment of rare genetic disorders and metabolic conditions.
Partnerships
BioMarin Pharmaceutical has established several significant partnerships and collaborations in the biotech industry, including:
- Howard University College of Pharmacy - BioMarin partnered with Howard University to develop a two-year fellowship in regulatory affairs aimed at early-career professionals with a PharmD or Ph.D.
- MiNA Therapeutics - BioMarin entered a research collaboration with MiNA Therapeutics to discover and develop RNAa therapeutic candidates targeting rare genetic diseases.
- Skyline Therapeutics - BioMarin announced a strategic collaboration with Skyline Therapeutics to develop novel gene therapies for cardiovascular diseases.
- ARUP Laboratories - BioMarin has partnered with ARUP Laboratories and Medicover to expand access to diagnostic testing in Europe, facilitating better healthcare services related to their products.
Regulatory Approvals
BioMarin Pharmaceutical has received several regulatory approvals for its products, including:
- BRINEURA (cerliponase alfa) - Approved by the FDA as the first treatment for children with CLN2 disease.
- VOXZOGO (vosoritide) - Approved by the FDA for increasing linear growth in children with achondroplasia aged 5 and up.
- Aldurazyme (laronidase) - Received marketing approval in Japan.
- Valoctocogene roxaparvovec - A biologics license application (BLA) was accepted by the FDA for this gene therapy for adults with severe hemophilia A.
Additionally, BioMarin has received Breakthrough Therapy Designation from the FDA for its gene therapy for hemophilia A.
Find more companies like BioMarin
See something that needs updating? Suggest edits to this profile.
